Atara Biotherapeutics, Inc. (ATRA) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
3.56
↓-51% vs avg
5yr avg: 7.22
30Y Low7.2·High7.2
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 3.96
30Y Low1.3·High5.3
ROE
↓
N/A
—
5yr avg: -739.6%
30Y Low-278%·High-81%
Debt/EBITDA
1.39
+0% vs avg
5yr avg: 1.39
30Y Low1.4·High1.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ATRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Atara Biotherapeutics, Inc. trades at 3.9x earnings, 44% below its 5-year average of 7.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 82%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $91M | $230M | $100M | $54M | $335M | $1.5B | $1.5B | $845M | $1.5B | $541M | $408M |
| Enterprise Value | $135M | $274M | $118M | $86M | $313M | $1.4B | $1.3B | $786M | $1.5B | $461M | $360M |
| P/E Ratio → | 3.92 | 7.04 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.75 | 1.90 | 0.77 | 6.34 | 5.26 | 72.58 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 2.64 | 5.28 | 3.14 | 2.91 | 4.49 | 3.04 | 1.61 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ATRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Atara Biotherapeutics, Inc.'s enterprise value stands at 3.6x EBITDA, 51% below its 5-year average of 7.2x. The Healthcare sector median is 14.2x, placing the stock at a 75% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.27 | 0.92 | 10.07 | 4.93 | 68.75 | — | — | — | — | — |
| EV / EBITDA | 3.56 | 7.22 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 3.77 | 7.52 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ATRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Atara Biotherapeutics, Inc. earns an operating margin of 29.7%. Operating margins have expanded from -3219.5% to 29.7% over the past 3 years, signaling improving operational efficiency. ROIC of 462.6% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.4% | 82.4% | 83.7% | -3.7% | 100.0% | -1286.4% | — | — | — | — | — |
| Operating Margin | 29.7% | 29.7% | -64.7% | -3219.5% | -441.2% | -1673.9% | — | — | — | — | — |
| Net Profit Margin | 27.1% | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -2014.9% | -112.4% | -91.7% | -81.4% | -92.4% | -892.9% | -553.7% | -277.9% |
| ROA | 50.5% | 50.5% | -62.2% | -101.9% | -54.1% | -64.4% | -65.9% | -79.2% | -756.9% | -496.1% | -268.5% |
| ROIC | 462.6% | 462.6% | — | -1083.7% | -137.0% | -106.7% | -91.1% | -86.8% | -94.2% | -59.9% | -24.5% |
| ROCE | 675.0% | 675.0% | — | -172.1% | -85.0% | -78.5% | -76.2% | -89.9% | -87.5% | -54.7% | -28.5% |
ATRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Atara Biotherapeutics, Inc. carries a Debt/EBITDA ratio of 1.4x, which is manageable (57% below the sector average of 3.2x). Net debt stands at $44M ($53M total debt minus $8M cash). Interest coverage of 9.6x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.57 | 0.10 | 0.03 | 0.05 | 0.00 | — | — |
| Debt / EBITDA | 1.39 | 1.39 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.17 | -0.28 | -0.40 | -0.20 | -0.18 | -0.45 | -0.19 |
| Net Debt / EBITDA | 1.17 | 1.17 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 9.63 | 9.63 | -17.51 | -51.24 | -611.04 | — | — | — | — | — | — |
ATRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.82x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.72x to 0.82x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.82 | 0.82 | 0.48 | 0.72 | 3.74 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
| Quick Ratio | 0.82 | 0.82 | 0.40 | 0.65 | 3.72 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
| Cash Ratio | 0.57 | 0.57 | 0.32 | 0.36 | 3.08 | 3.51 | 6.04 | 7.05 | 7.74 | 6.01 | 26.43 |
| Asset Turnover | — | 5.97 | 1.18 | 0.05 | 0.17 | 0.04 | — | — | — | — | — |
| Inventory Turnover | — | — | 1.97 | 0.92 | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 3.79 | 4.20 | 1452.17 | 230.93 | 17.69 | — | — | — | — | — |
ATRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Atara Biotherapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 25.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 25.5% | 14.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $13M | $7M | $4M | $4M | $4M | $3M | $2M | $2M | $1M | $1M |
Peer Comparison
Compare ATRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ATRAYou | $91M | 3.9 | 3.6 | — | 82.4% | 29.7% | — | 462.6% | 1.4 |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 ADCT | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 CABA | $463M | -1.7 | — | — | — | — | -127.0% | -429.6% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CELC | $4B | -23.2 | — | — | — | — | -163.8% | -80.4% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ATRA — Frequently Asked Questions
Quick answers to the most common questions about buying ATRA stock.
What is Atara Biotherapeutics, Inc.'s P/E ratio?
Atara Biotherapeutics, Inc.'s current P/E ratio is 3.9x. The historical average is 7.0x.
What is Atara Biotherapeutics, Inc.'s EV/EBITDA?
Atara Biotherapeutics, Inc.'s current EV/EBITDA is 3.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.2x.
Is ATRA stock overvalued?
Based on historical data, Atara Biotherapeutics, Inc. is trading at a P/E of 3.9x. Compare with industry peers and growth rates for a complete picture.
What are Atara Biotherapeutics, Inc.'s profit margins?
Atara Biotherapeutics, Inc. has 82.4% gross margin and 29.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Atara Biotherapeutics, Inc. have?
Atara Biotherapeutics, Inc.'s Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.